VX-264

Vertex Pharmaceuticals Incorporated · Phase 1 active Small molecule

At a glance

Generic name	VX-264
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VX-264 CI brief — competitive landscape report
VX-264 updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI